Kumar Rohit J, Kimble Roy M, Boots Robert, Pegg Stuart P
Stuart Pegg Burns Unit, Royal Children's Hospital, Brisbane, Queensland, Australia.
ANZ J Surg. 2004 Aug;74(8):622-6. doi: 10.1111/j.1445-1433.2004.03106.x.
The purpose of the present study was to compare the effectiveness of three burns dressings (TransCyte, a bio-engineered skin substitute; Biobrane; and Silvazine cream (silver sulphadiazine and 0.2% chlorhexidine)), in treating children with partial-thickness burns. The primary objective was to determine the days until > or =90% re-epithelialization. The secondary objectives were to evaluate the number of wounds requiring autografting and the number of dressing changes/local wound care required.
Study wounds were identified on each patient and the patients were randomized to receive TransCyte or Biobrane or Silvazine. Assessment of study wound closure began at 2 days after treatment and continued at least every other day thereafter until the wounds re-epithelialized or were autografted. A laser Doppler imaging system was used as an adjunct to assessing the depth of the burn.
Thirty-three patients with 58 wound sites enrolled in the study (TransCyte, n = 20, Biobrane, n = 17; Silvazine, n = 21). Mean time to re-epithelialization was 7.5 days for TransCyte, 9.5 days for Biobrane, and 11.2 days for Silvazine. The number of wounds requiring autografting were 5/21 (24%) for Silvazine, 3/17 (17%) for Biobrane, and 1/20 (5%) for TransCyte.
When used in partial-thickness burns in children, TransCyte promotes fastest re-epithelialization and required less overall dressings then Biobrane or Silvazine. Patients who received Silvazine or Biobrane require more autografting than those treated with TransCyte.
本研究的目的是比较三种烧伤敷料（TransCyte，一种生物工程皮肤替代物；Biobrane；以及Silvazine乳膏（磺胺嘧啶银和0.2%洗必泰））治疗儿童浅度烧伤的效果。主要目标是确定达到≥90%再上皮化所需的天数。次要目标是评估需要自体移植的伤口数量以及所需的换药次数/局部伤口护理次数。
在每位患者身上确定研究伤口，患者被随机分配接受TransCyte、Biobrane或Silvazine治疗。治疗后第2天开始评估研究伤口的闭合情况，此后至少每隔一天评估一次，直至伤口再上皮化或进行自体移植。使用激光多普勒成像系统辅助评估烧伤深度。
33例患者共58个伤口部位纳入研究（TransCyte组20例，Biobrane组17例，Silvazine组21例）。TransCyte组再上皮化的平均时间为7.5天，Biobrane组为9.5天，Silvazine组为11.2天。需要自体移植的伤口数量，Silvazine组为5/21（24%），Biobrane组为3/17（17%），TransCyte组为1/20（5%）。
用于儿童浅度烧伤时，TransCyte促进再上皮化的速度最快，且总体所需敷料比Biobrane或Silvazine少。接受Silvazine或Biobrane治疗的患者比接受TransCyte治疗的患者需要更多的自体移植。
